News | May 11, 2015

Boston Scientific Details Cardiology Growth and Expansion Plans to Investors

Presentation highlights include European launches for Watchman and Eluvia, expected FDA approval of Synergy bioabsorbable stent

Boston Scientific, investors, cardiology, growth, expansion

May 11, 2015 — Boston Scientific Corp. presented an overview of its continued business momentum and long-term growth strategies at a meeting with the investment community May 1.

In the cardiovascular space, Boston Scientific continues to advance its drug-eluting stent portfolio with the ongoing clinical program for the Synergy everolimus-eluting bioabsorbable polymer platinum chromium coronary stent; U.S. Food and Drug Administration (FDA) approval is expected by year-end 2015. The company also announced the internal development of a fully resorbable stent platform.

New agreements with MedAxiom and TogetherMD are focused on improving clinical outcomes and lowering costs of delivering cardiovascular care through customized programs.

In the company's emerging structural heart business, next generations of the Watchman left atrial appendage closure platform and the Lotus Valve platform are planned to launch in Europe later this year.  

In peripheral intervention, the company is broadening its atherectomy and thrombectomy portfolio with its integration of the Bayer AG's Interventional business and a U.S. distribution agreement with C.R. Bard Inc. for the Lutonix drug coated balloon. Boston Scientific's Eluvia drug-eluting vascular stent system* is expected to launch in Europe in 2016 and enrollment continues in a novel clinical trial of its Vessix renal denervation system for patients with hypertension.

In cardiac rhythm management, the company focused on the soon-to-be-launched second-generation Emblem subcutaneous implantable defibrillator system (S-ICD). Boston Scientific presented plans for achieving magnetic resonance imaging (MRI) conditional-safe labeling across its pacemaker and ICD, S-ICD and cardiac resynchronization therapy defibrillator (CRT-D) platforms. Additionally, a leadless pacemaker development program will target the ability to pair with the Emblem S-ICD.

The company also plans to deliver next-generation ablation catheter platforms including an open irrigated version of IntellaTip MiFi and the IntellaNav family of navigation-enabled catheters. Both devices are expected to be built upon the foundation of technologies such as the EnduraLife battery technology and Rhythmia mapping system.

For more information: www.bostonscientific.com

Related Content

Resolute Onyx Stent With Improved Radiographic Visibility Found to Be Safe and Effective
News | Stents Drug Eluting | October 01, 2018
October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer-c
Boston Scientific Receives FDA Approval for Eluvia Drug-Eluting Vascular Stent
Technology | Stents Drug Eluting | October 01, 2018
Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA)...
Eluvia Drug-Eluting Stent Demonstrates Superior Patency in IMPERIAL Trial
News | Stents Drug Eluting | September 26, 2018
Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 Transcatheter Cardiovascular...
Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
Overlay Init